




The relative strengths and weaknesses of Kura Oncology Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kura Oncology Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 156% points. The greatest weakness of Kura Oncology Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 395%, being 132% points above the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	86,869
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,055
Liabilities, Non-Current	101
Other Assets	319
Other Compr. Net Income	-87
Other Expenses	23,865
Other Liabilities	0
Other Net Income	1,240
Other Revenues	0
Property and Equipment	71
Research and Development	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	87,259
Liabilities	5,156
Expenses	23,865
Revenues	0
Stockholders Equity	82,103
Net Income	-22,625
Comprehensive Net Income	-22,668
BaseVar	58,804
ECR before LimitedLiability	338%
Economic Capital Ratio	395%